Nkarta to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in two investor conferences:

• 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:00 p.m. ET - featuring a fireside chat.
• Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET - featuring a panel discussion.

Webcasts of these events will be available on the Investors section of Nkarta's website, with replays archived for approximately 90 days. Nkarta specializes in off-the-shelf NK cell therapies aimed at providing broad access and deep anti-tumor activity in outpatient settings, utilizing advanced cell engineering technologies.

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

22^nd Annual Needham Virtual Healthcare Conference
April 17, 2023
3:00 p.m. ET – fireside chat

Canaccord Genuity Horizons in Oncology Virtual Conference
April 20, 2023
3:00 p.m. ET – panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for patients with cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

FAQ

What investor conferences is Nkarta participating in April 2023?

Nkarta is participating in the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, and the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023.

What time are Nkarta's conference presentations scheduled?

Nkarta's presentations are scheduled for April 17, 2023, at 3:00 p.m. ET for the Needham conference, and April 20, 2023, at 3:00 p.m. ET for the Canaccord conference.

Where can I watch Nkarta's conference presentations?

Nkarta's conference presentations will be available via webcast on the Investors section of their website, with replays archived for about 90 days.

What is Nkarta's focus in biotechnology?

Nkarta focuses on developing engineered natural killer (NK) cell therapies to treat cancer, utilizing advanced cell expansion and engineering technologies.

What innovations does Nkarta utilize in their therapies?

Nkarta employs proprietary cell engineering technologies and CRISPR-based genome engineering in its NK cell therapies.